Abstract:The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause for the ongoing global public health emergency. It is more commonly known as coronavirus disease 2019 (COVID-19); the pandemic threat continues to spread aroundthe world with the fluctuating emergence of its new variants. The severity of COVID-19 ranges from asymptomatic to serious acute respiratory distress syndrome (ARDS), which has led to a high human mortality rate and disruption of socioeconomic well-being. For the restoration of pre-pandemic normalcy, the international scientific community has been conducting research on a war footing to limit extremely pathogenic COVID-19 through diagnosis, treatment, and immunization. Since the first report of COVID-19 viral infection, an array of laboratory-based and point-of-care (POC) approaches have emerged for diagnosing and understanding its status of outbreak. The RT-PCR-based viral nucleic acid test (NAT) is one of the rapidly developed and most used COVID-19 detection approaches. Notably, the current forbidding status of COVID-19 requires the development of safe, targeted vaccines/vaccine injections (shots) that can reduce its associated morbidity and mortality. Massive and accelerated vaccination campaigns would be the most effective and ultimate hope to end the COVID-19 pandemic. Since the SARS-CoV-2 virus outbreak, emerging biotechnologies and their multidisciplinary approaches have accelerated the understanding of molecular details as well as the development of a wide range of diagnostics and potential vaccine candidates, which are indispensable to combating the highly contagious COVID-19. Several vaccine candidates have completed phase III clinical studies and are reported to be effective in immunizing against COVID-19 after their rollout via emergency use authorization (EUA). However, optimizing the type of vaccine candidates and its route of delivery that works best to control viral spread is crucial to face the threatening variants expected to emerge over time. In conclusion, the insights of this review would facilitate the development of more likely diagnostics and ideal vaccines for the global control of COVID-19.

The immunology of SARS-CoV-2 infections and vaccines

SARS-CoV-2: Mapping its features that made it as a unique virus

Immune response scenario and vaccine development for SARS-CoV-2 infection

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects

SARS-CoV-2: vaccines in the pandemic era

Development of SARS-CoV-2 Vaccine: Challenges and Prospects

Status Report on COVID-19 Vaccines Development

SARS-CoV-2: An Analysis of the Vaccine Candidates Tested in Combatting and Eliminating the COVID-19 Virus

Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2

SARS-CoV-2 Variants, Vaccines, and Host Immunity

The way of SARS-CoV-2 vaccine development: success and challenges

An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

SARS-CoV-2 Vaccine Development: Current Status

Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms

SARS-CoV-2 Vaccine Development and Challenges

Coronavirus vaccine development: from SARS and MERS to COVID-19

SARS-CoV-2 Vaccines: Status Report

COVID-19 vaccine: where are we now and where should we go?

Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

A systematic review of SARS-CoV-2 vaccine candidates